Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0033 | 0.0742 | 0.1054 |
Onchocerca volvulus | Alhambra homolog | 0.0028 | 0 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0028 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.314 | 0.6092 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.5155 | 0.7321 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.0742 | 0.144 |
Echinococcus multilocularis | tar DNA binding protein | 0.0061 | 0.5155 | 0.5155 |
Echinococcus multilocularis | jumonji domain containing protein | 0.0039 | 0.1721 | 0.1721 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0048 | 0.312 | 0.312 |
Echinococcus granulosus | lysine specific demethylase 5A | 0.0034 | 0.0925 | 0.0925 |
Echinococcus multilocularis | lysine specific demethylase 5A | 0.0034 | 0.0925 | 0.0925 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0048 | 0.312 | 0.312 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0061 | 0.5155 | 0.5155 |
Plasmodium falciparum | phd finger protein, putative | 0.0028 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0061 | 0.5155 | 1 |
Toxoplasma gondii | PHD-finger domain-containing protein | 0.0028 | 0 | 0.5 |
Echinococcus granulosus | Transcription factor JmjC domain containing protein | 0.0092 | 1 | 1 |
Toxoplasma gondii | PHD-finger domain-containing protein | 0.0028 | 0 | 0.5 |
Schistosoma mansoni | jumonji domain containing protein | 0.0073 | 0.7041 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0061 | 0.5155 | 0.5155 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0048 | 0.312 | 0.6053 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0034 | 0.0925 | 0.1794 |
Echinococcus granulosus | jumonji domain containing protein | 0.0039 | 0.1721 | 0.1721 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0034 | 0.0925 | 0.1313 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0061 | 0.5155 | 1 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0034 | 0.0925 | 0.1313 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.312 | 0.6053 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.5155 | 0.7321 |
Brugia malayi | TAR-binding protein | 0.0061 | 0.5155 | 0.5155 |
Echinococcus multilocularis | Transcription factor, JmjC domain containing protein | 0.0092 | 1 | 1 |
Giardia lamblia | PHD finger protein 15 | 0.0028 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.5155 | 0.7321 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.5155 | 0.7321 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.5155 | 0.7321 |
Brugia malayi | jmjC domain containing protein | 0.0034 | 0.0925 | 0.0925 |
Loa Loa (eye worm) | TAR-binding protein | 0.0061 | 0.5155 | 1 |
Brugia malayi | RNA binding protein | 0.0061 | 0.5155 | 0.5155 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0058 | 0.468 | 0.9079 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0033 | 0.0742 | 0.0742 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 2.51 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 2.68 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 3.68 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 4 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 33 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 100 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 100 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 9.56 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 4 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 33 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 100 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 101 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
XC50 (functional) | = 6.91 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 0.12383 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.